Light Horse’s CEO said the biotech’s initial focus will be on “high-value and historically challenging” oncology targets.

MitoRx Therapeutics (MitoRx), a platform biotechnology company developing novel mitochondrial-targeted sulfide-donor therapeutics (mtH2SD) in obesity-related disorders and myopathies announces the ...

A major population proteomics study using UK Biobank patient samples backed by 14 pharma companies has launched today with ...

In the span of eight months, Big Pharma companies took over four of the hottest radiopharmaceutical players in the industry.

Scientists have long considered ketones (a fundamental chemical class) and esters (molecules formed when an acid reacts with an alcohol) to be locked treasure chests of possibilities.

JP Morgan highlights mixed sentiment for U.S. large-cap biopharma stocks as advancements in obesity drugs and key product launches shape 2025 outlook.

Medicare’s drug pricing negotiations — the first of their kind in the United States, passed under President Joe Biden — face ...

Initial rounds of VC financing totaled $7.7 billion over 137 deals for biopharma in 2024, compared to $3.8 billion over 156 ...

The UK's self-regulated system for disclosing payments from drug companies to healthcare professionals and organizations is ...

This double-digit growth in new drug sales showcases the company's ability to successfully commercialize cutting-edge ...

The Biden administration’s justification of the first cycle of Medicare drug price negotiations is fueling curiosity and ...